High Inflation Puts...
Health Care: Drugs
Targeted Genetics Corporation (TGEN: OTC)
$0.29 0.02 | 5.59%
03/08/11 - 03:09 PM ET
4.74K / 414.00K
Vol / Avg. Vol:0.29 / 0.27
Open / Prev. Close:0.27 - 0.29
Today's Range:0.17 - 0.50
52 Wk Range:-19.64%
Performance YTD:TheStreet Rating:
Portfolios with TGEN
- Portfolio NameUser Type
- Usermsrapp
- Userann's prorfolio
- Usersteves #1
- UserKleenex
- Usermicknorton Portfolio 1
- Usermicknorton
- UserSusan Daluisio Portfolio 1
- UserASPSC
- Userffoltyn Portfolio 1
- UserCheap spec
Latest TGEN Headlines from TheStreet
- Targeted Genetics Sells Assets To Genzyme 09.09.09 | 11:09 am
- Targeted Genetics' Net Loss Widens 04.01.09 | 02:04 pm
- Dendreon Posts Widened Loss, Explains Provenge Changes 03.13.08 | 04:03 pm
- Targeted Genetics Reports Wider Loss 08.06.07 | 10:08 pm
- Wednesday's Small-Cap Winners & Losers 07.25.07 | 04:07 pm
- These Gene-Drug Stocks Are Getting Hot 07.12.07 | 06:07 am
- Thursday's Small-Cap Winners & Losers 06.20.07 | 01:06 am
- Tuesday's Health Winners & Losers 12.12.06 | 01:12 pm
- Monday's Small-Cap Winners & Losers 11.27.06 | 03:11 pm
- Thursday's Health Winners & Losers 11.09.06 | 01:11 pm
Press Releases for TGEN
- Targeted Genetics To Host Conference Call And Webcast Discussion Of Annual Shareholders Meeting On February 18, 2011 - Business Wire 02.15.11 | 04:02 pm
- Targeted Genetics Corporation Updates Investors On Annual Meeting Matters - Business Wire 01.07.11 | 08:01 am
- Targeted Genetics Corporation Completes Acquisition Of Biocontrol Limited - Business Wire 01.07.11 | 08:01 am
- Targeted Genetics Corporation Updates Investors On Annual Meeting Matters - Business Wire 12.08.10 | 05:12 pm
- Koyote Trading Welcomes Washington State Court Decision On Targeted Genetics’ Annual Meeting - Business Wire 12.07.10 | 08:12 am
- Targeted Genetics Corporation Announces Annual Meeting Date - Business Wire 11.29.10 | 06:11 am
- Targeted Genetics Corporation Announces Plan For Next Annual Meeting - Business Wire 11.18.10 | 05:11 pm
- Targeted Genetics’ Partner Celladon Corporation Reports 12 Month Follow Up Data From Phase 2 Clinical Trial Of Patients Treated With MYDICAR® - Business Wire 11.15.10 | 12:11 pm
- Targeted Genetics Corporation Reports Fourth Quarter And Full Year 2009 Financial Results - Business Wire 06.01.10 | 06:06 am
- Targeted Genetics’ Partner Celladon Corporation Reports Positive Phase 2 Clinical Trial Data At Heart Failure Association Annual Meeting - Business Wire 05.30.10 | 09:05 am
Partner Headlines for TGEN
- Zacks' Voice of the People highlights opportunities with Targeted Genetics and Aastrom Biosciences - Press Releases - Zacks 05.28.10 | 09:05 am
- Biotech Calendar: Key Dates for Wild Pennies - Voice of the People - Zacks 05.27.10 | 05:05 pm
